Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
about
Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular PolypillThe rational patient and beyond: implications for treatment adherence in people with psychiatric disabilitiesMedicaid prescription limits: policy trends and comparative impact on utilization.How do we improve patient compliance and adherence to long-term statin therapy?Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature ReviewAdherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart diseaseA randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]Gender differences in aspirin use among adults with coronary heart disease in the United StatesLong-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocolThe effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic reviewAdherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.Alternative Strategies to Achieve Cardiovascular Mortality Goals in China and India: A Microsimulation of Target- Versus Risk-Based Blood Pressure Treatment.Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Improving adherence to medication in stroke survivors (IAMSS): a randomised controlled trial: study protocol.Prevalence and Access of Secondary Source Medication Data: Evaluation of the Southeastern Diabetes Initiative (SEDI)Noncompliance in the use of cardiovascular medications in the Medicare Part D populationDoes the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort studyUse of evidence-based cardiac prevention therapy among outpatients with atrial fibrillationAnother treatment gap: restarting secondary prevention medications: the Women's Health Initiative.Physician nonadherence with a hepatitis C screening program.Case-control study of aspirin use and risk of pancreatic cancer.What do we know about adherence and self-care?Recent hospitalization for non-coronary events and use of preventive medications for coronary artery disease: an observational cohort studyIvabradine: the evidence of its therapeutic impact in angina.Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease.Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data.Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital dischargeAchievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS Study (REasons for Geographic And Racial Differences in Stroke).The effect of post-discharge educational intervention on patients in achieving objectives in modifiable risk factors six months after discharge following an episode of acute coronary syndrome, (CAM-2 Project): a randomized controlled trial.Improving medication adherence in hypercholesterolemia: challenges and solutions.Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery diseaseMedication adherence: WHO cares?Medication non-adherence after myocardial infarction: an exploration of modifying factorsMedication Discussion Questions (MedDQ): developing a guide to facilitate patient-clinician communication about heart medications.Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologiesRacial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarctionUse of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012).Reduction of cardiac and aortic cholesterol in hypercholesterolemic rats fed esters of phytosterol and omega-3 fatty acids.The burden of non-adherence to cardiovascular medications among the aging population in Australia: a meta-analysis.
P2860
Q26753102-3B09AC21-B7B6-456C-BD3E-97C62748B650Q26864657-67DA9E2F-7129-4006-8708-E4372226F29EQ27306989-49E8AD99-235E-4523-AA55-6898ECCDEB3AQ27691392-A17734C9-3553-4D2D-AC04-D7EC2145A446Q28073813-39CA6B53-0E75-465D-BD90-5E781B779A3FQ28212736-10951058-AAEE-4E0B-BCA3-A53DD6B59850Q28218403-99A62A37-65D7-4AAD-8F0B-8722D5FEC31BQ28220649-877DABC6-4410-4FB6-A407-097C9F0FE3EEQ28655596-9374D476-3C3E-4739-B8F6-24D37C438EF6Q28709939-8FC25485-863E-46EC-98E2-CA954BF8E109Q30248710-AE9E5386-C214-4098-9040-6624C253FD60Q30378567-99DD025E-67F0-439E-938C-DB9D7FE1DB75Q30457290-13CF4AF4-ED64-48BF-8F72-CEA220AE1F8EQ30493675-1A572EBB-E03C-48FA-BED4-3D7005AA8F24Q30989684-D32C9859-F505-4BF7-9FD3-CABB4EA95C36Q33567812-33AE274C-1833-443B-BB17-213DE6415E9EQ33582496-3D33C5A2-8BE8-44AE-9024-0525C1912F83Q33680031-08423882-5F60-4C67-8D4C-50AB95EA81C8Q33752799-93CB1E83-3814-4949-8F26-D2B29721C40AQ33778635-1DC0B720-C585-4F75-B97B-C1A191D93AF8Q33881059-0939E5B3-3DC4-432F-8C24-16C0BF52C25CQ33892184-4A5AE85F-A805-49D9-A1AF-EED40DCB822AQ33955960-A5333F5D-DBB0-46C8-A596-0286DA38F333Q33973963-8ECE7B68-3B47-4E5E-BCDA-D6F8AE193DF3Q34169705-4EB56906-F052-4AC5-BAB3-AFD253807AC3Q34220461-B4DF5B0D-0F0B-4EB3-A0A7-AC3EF10F3A6BQ34274017-5EE94922-86E0-4839-AED4-8EDA9FBE0B77Q34364029-2836D1AD-2D56-4766-AAF4-90FF503E1D6EQ34408135-D35CD75B-450D-4E4D-9275-68ECB52A1851Q34482456-A58CFF6E-01EE-49D0-829E-F7C085E1D198Q34566413-FF400AA1-130C-43A4-8D5C-0CE198573D24Q34627451-941762CB-996B-4121-80CA-24972D671E30Q34826463-3135D9DC-19D3-4FB6-B78E-619E8964A526Q35042827-71F816F0-7EDC-455B-A138-26ECC51EE10CQ35086213-27C1EE3F-553E-425A-B660-A314ECE80841Q35153905-915CDF00-2270-49BC-8A8B-8BF035596733Q35178428-FF4CF32C-6807-4A34-96ED-C699594466B5Q35193736-00B9CE02-3488-4F9E-AA6E-998B25D7681AQ35420022-DB341CAB-6636-4CF5-B3A7-0C4E6D9F3E3BQ35573404-0098662C-360C-4631-BB4B-2BA4DEB76C3B
P2860
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term adherence to evidenc ...... ies in coronary artery disease
@ast
Long-term adherence to evidenc ...... ies in coronary artery disease
@en
Long-term adherence to evidenc ...... ies in coronary artery disease
@nl
type
label
Long-term adherence to evidenc ...... ies in coronary artery disease
@ast
Long-term adherence to evidenc ...... ies in coronary artery disease
@en
Long-term adherence to evidenc ...... ies in coronary artery disease
@nl
prefLabel
Long-term adherence to evidenc ...... ies in coronary artery disease
@ast
Long-term adherence to evidenc ...... ies in coronary artery disease
@en
Long-term adherence to evidenc ...... ies in coronary artery disease
@nl
P2093
P3181
P1433
P1476
Long-term adherence to evidenc ...... ies in coronary artery disease
@en
P2093
Anita Y Chen
Bradley G Hammill
Elizabeth R DeLong
Judith M Kramer
Lawrence H Muhlbaier
Nancy M Allen LaPointe
P304
P3181
P356
10.1161/CIRCULATIONAHA.105.505636
P407
P577
2006-01-17T00:00:00Z